

San Antonio Breast Cancer Symposium

Henry B. Gonzalez Convention Centre

December 9-12, 2025

Abstracts

CCTG MA.27 - A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer

Type: Poster

Session: Poster Session 3

Abstract: **Survivor plots for quantitated adjunctive statistically standardized ER, PgR, and HER2 in adjuvant postmenopausal breast cancer: Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole**

Abstract #: PS3-07-23

Authors: J.W. Chapman; J. Bayani; S. SenGupta; J.M.S. Bartlett; T. Piper; M.A. Quintayo; S. Virk; P.E. Goss; J.N. Ingle; M.J. Ellis; G.W. Sledge; G.T. Budd; M. Rabaglio; R.H. Ansari; R. Tozer; D.P. D'Souza; H. Chalchal; S. Spadafora; V. Stearns; E.A. Perez; K.A. Gelmon; T.J. Whelan; C. Elliott; L.E. Shepherd; B.E. Chen; K.J. Taylor

Link: <https://doi.org/10.1158/1557-3265.SABCS25-PS3-07-23>

CCTG MA.32 - A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer

Type: Poster

Session: Poster Session 4

Abstract: **Standardized Definitions for Efficacy End Points (STEEP, STEEP2) in the CCTG MA.32 randomized breast cancer trial of metformin versus placebo: Implications of the type of recurrence and new non-breast cancer primary on outcome assessment**

Abstract #: PS4-08-11

Authors: K.J. Jerzak; W.R. Parulekar; B.E. Chen; A.E. Lohmann; P.J. Goodwin

Link: <https://doi.org/10.1158/1557-3265.SABCS25-PS4-08-11>

CCTG MA.32D/Alliance A211201 - Change In Mammographic Density with Metformin Use: A Companion Study to NCIC CTG Study MA.32

Type: Poster

Session: Poster Session 3

Abstract: **Change in mammographic density (MD) with metformin use: Alliance A211201, A companion study to NCIC study MA.32**

Abstract #: PS3-01-30

Authors: M. Wood; M.I. Elsaid; L.J. Grimm; H. Liu; C. Oswald; C.S. Kuzma; I. Bedrosian; J. Ligibel; P.J. Goodwin

Link: <https://doi.org/10.1158/1557-3265.SABCS25-PS3-01-30>

CCTG MA.37/ BIG 14-03 - PALLAS: PALbociclib CoLLaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

Type: Oral

Session: Rapid Fire 3

Abstract: Tumor-informed circulating tumor DNA analysis to assess molecular residual disease for prognosis and prediction of benefit from palbociclib in the PALLAS trial

Abstract #: RF3-04

Authors: H.A. Parsons; K. Ballman; E. Heitzer; M. Watson; M. Balic; D. Hlauschek; D. Renner; E. Kalashnikova; G. Steger; J.M. Balko; Y. Novik; M. Martin; A.A. Rodriguez; Z. Dayao; A. Chan; E. Nili Gal-Yam; M.C. Liu; C. Isaacs; M. Los; M. Gil Gil; B. Felder; C. Denkert; P. Fasching; F. Liu; T. O'Donnell; E.L. Mayer; M. Gnant; W.F. Symmans; A. DeMichele

Link: <https://doi.org/10.1158/1557-3265.SABCS25-RF3-04>

CCTG MA.37/ BIG 14-03 - PALLAS: PALbociclib CoLLaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

Type: Poster

Session: Poster Session 3

Abstract: Long-term prognostic and predictive value of lobular histology in the PALLAS trial

Abstract #: PS3-11-06

Authors: G. Nader-Marta; C. Desmedt; D. Hlauschek; A. DeMichele; G. Zoppoli; E. Blondeaux; E. de Azambuja; M. Bellet-Ezquerria; O. Metzger-Filho; J. M. Suga; G. Pfeiler; M. P. Goetz; M. Ruiz-Borrego; S. Loibl; J. Meisel; A. Ring; K. Van Baelen; E. P. Mamounas; N. Zdenkowski; E. Agostinnetto; M. Lambertini; E. Gauthier; L. Soelkner; A. C. Dueck; M. Gnant;

Link: <https://doi.org/10.1158/1557-3265.SABCS25-PS3-11-06>

CCTG MAC.15/ SWOG S1007– A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy Plus or Minus Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx For Positive Node, Endocrine Responsive Breast Cancer

Type: Poster

Session: Poster Spotlight 12

Abstract: Sentinel Lymph Node Biopsy and Clinical Outcome of Patients with Node-Positive Breast Cancer in the RxPONDER Trial (S1007)

Abstract #: PD12-05

Authors: R.F. Hwang; W.E. Barlow; K. Kalinsky; R. Jagsi; L. Pusztai; A. Thompson; G.N. Hortobagyi; P. Sharma; F. Meric-Bernstam

Link: <https://doi.org/10.1158/1557-3265.SABCS25-PD12-05>

CCTG MAC.20/ ALLIANCE A011404 - Randomized Phase III Trial Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Type: Poster
Session: Poster Spotlight 8
Abstract: **Weight Trajectories in the Breast Cancer Weight Loss (BWEL) Trial (Alliance)**
Abstract #: PD8-01
Authors: C. Cao, K.V. Ballman, L. McCall, C.M. Alfano, X. Feng, L.M. Delahanty, E. Frank, O. Hahn, D.L. Hershman, J.O. Hopkins, M. Irwin, E.L. Mayer, L. Minasian, L. Nebeling, M.L. Neuhouser, E.D. Paskett, P.A. Spears, V. Stearns, C.A. Thomson, A. Weiss, J. White, P.J. Goodwin, C. Hudis, E.P. Winer, A.H. Partridge, L.A. Carey, J.A. Ligibel
Link: <https://doi.org/10.1158/1557-3265.SABCS25-PD8-01>

CCTG MAC.20/ ALLIANCE A011404 - Randomized Phase III Trial Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Type: Poster
Session: Poster Session 4
Abstract: **Variation in weight loss and intervention engagement in the Breast Cancer Weight Loss (BWEL) trial by language and ethnicity (Alliance)**
Abstract #: PS4-09-29
Authors: A. Odai-Afotey, K. V. Ballman, L. M. McCall, C. Cao, C. Alfano, V. Bernstein, T. E. Crane, L. M. Delahanty, L. Frank, P. J. Goodwin, O. Hahn, D. L. Hershman, J. O. Hopkins, M. Irwin, E. L. Mayer, L. Minasian, L. Nebeling, M. Neuhouser, E. D. Paskett, P. A. Spears, V. Stearns, C. A. Thomson, T. A. Wadden, A. Weiss, J. White, C. Hudis, E. P. Winer, L. Carey, A. H. Partridge, J. Ligibel
Link: <https://doi.org/10.1158/1557-3265.SABCS25-PS4-09-29>

CCTG MAC.28/ NRG-BR007 – A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage 1, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score ≤ 18 Breast Cancer (DEBRA)

Type: Poster
Session: Poster Session 5
Abstract: **A phase III trial evaluating De-escalation of Breast Radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤ 18 breast cancer: NRG-BR007**
Abstract #: PS5-08-20
Authors: J.R. White; R.S. Cecchini; E.E. Harris; E.P. Mamounas; J.G. Bazan; D.G. Stover; P.A. Ganz; R. Jagsi; S.J. Anderson; C. Bergom; V. Théberge; M.B. El-Tamer; R.C. Zellars; D.A. Shumway; G. Chen; T.B. Julian; N. Wolmark
Link: <https://doi.org/10.1158/1557-3265.SABCS25-PS5-08-20>

CCTG MAC.30/ NRG BR009 - A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score \leq 25 (OFSET)

Type: Poster

Session: Poster Session 5

Abstract: **NRG-BR009: A phase III trial evaluating addition of adjuvant chemotherapy to Ovarian Function Suppression + Endocrine Therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer and recurrence score \leq 25 (OFSET)**

Abstract #: P5-07-04

Authors: S. Swain; G. Tang; S.L. Puhalla; P.A. Ganz; N.L. Henry; R.S. Cecchini; S.A. Reid; P. Rastogi; C.E. Geyer, Jr.; J.R. White; A.S. Clark; T.C. Haddad; G.A. Vidal; N. Wolmark; E.P. Mamounas

Link: <https://doi.org/10.1158/1557-3265.SABCS25-PS5-07-04>
